Guillermo Garrido Rosa, MD
Pulmonary Disease · Orlando, FLNPI 1265669972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 31 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$256
- GSK$122
- Inspire Medical Systems, Inc.$113
- Genentech USA, Inc.$84
- United Therapeutics Corporation$78
- ANI Pharmaceuticals, Inc.$78
- plus $381 from 12 others
Across 5 payments — averaging $146.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$731
What the payments were for
- Food & beverage$1,09599%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 2 | $256 |
| GSK | 1 | $122 |
| Inspire Medical Systems, Inc. | 5 | $113 |
| Genentech USA, Inc. | 1 | $84 |
| United Therapeutics Corporation | 3 | $78 |
| ANI Pharmaceuticals, Inc. | 3 | $78 |
| Boehringer Ingelheim | 3 | $68 |
| Insmed, Inc. | 2 | $42 |
| Philips North America LLC | 2 | $41 |
| Sanofi | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Grifols USA, LLC | 1 | $28 |
| Viatris Specialty LLC | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Resmed Corp | 1 | $20 |
| Itamar Medical Inc | 1 | $20 |
| Baxter Healthcare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,112 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Orlando
- Ali JiwaniOrlando$859K
- Junaid MalikOrlando$429K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.